Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Heart Failure 2Breast Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Postoperative Complications 1Pheochromocytoma 1Pain, Postoperative 1Neoplasms 1Locally Advanced Head and Neck Squamous Cell Carcinoma 1Jaw Cysts 1Gastrointestinal Stromal Tumors 1Arrhythmias, Cardiac 1Agnosia 1

Interventions

Control Groups 2Atorvastatin 2sacubitril and valsartan sodium hydrate drug combination 1pertuzumab 1nicotinamide-beta-riboside 1empagliflozin 1dapagliflozin 1candesartan 1Trastuzumab 1Sodium Chloride 1Simendan 1Pyruvic Acid 1Population Groups 1Ogivri 1Metoprolol 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Eplerenone 1Carvedilol 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Heart Failure × Control Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

NCT03557255 2018-06-14

Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries

National Cancer Institute, Egypt

Phase 2 Completed
60 enrolled

Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡